FDA’s CDER is launching a new board — the Pharmaceutical Supply Chain Governance Board — to 'improve monitoring of the supply chain.'
It’s a result of the Covid-related shortages, and it's "tasked with coordinating all CDER supply-chain initiatives and providing guidance and fixes for major supply-chain issues."